A detailed history of Citigroup Inc transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 9,757 shares of INMB stock, worth $43,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,757
Previous 2,656 267.36%
Holding current value
$43,808
Previous $23,000 126.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.86 - $9.86 $34,510 - $70,015
7,101 Added 267.36%
9,757 $52,000
Q2 2024

Aug 12, 2024

SELL
$7.15 - $11.84 $324,524 - $537,393
-45,388 Reduced 94.47%
2,656 $23,000
Q1 2024

May 10, 2024

BUY
$10.53 - $14.01 $127,876 - $170,137
12,144 Added 33.83%
48,044 $564,000
Q4 2023

Feb 09, 2024

BUY
$6.6 - $11.52 $236,940 - $413,568
35,900 New
35,900 $404,000
Q2 2022

Aug 10, 2022

BUY
$5.48 - $8.97 $7,124 - $11,661
1,300 New
1,300 $11,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $80.6M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.